Overview A Study of IMR-687 in Subjects With Sickle Cell Disease Status: Active, not recruiting Trial end date: 2022-08-01 Target enrollment: Participant gender: Summary A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease Phase: Phase 2 Details Lead Sponsor: Imara, Inc.